Video content above is prompted by the following: How would you sequence epcoritamab, a CD20xCD3 bispecific antibody for patients with R/R DLBCL who have progressed beyond CAR T-cell therapy? How would you sequence glofitamab-gxbm, a CD20xCD3 bispecific antibody for patients with R/R DLBCL who have progressed beyond CAR T-cell therapy?